XRP44XMicrotubule depolymerization agent. Also Ras-Net pathway inhibitor CAS# 729605-21-4 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 729605-21-4 | SDF | Download SDF |
| PubChem ID | 10339779 | Appearance | Powder |
| Formula | C21H21ClN4O | M.Wt | 380.87 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in DMSO and to 50 mM in ethanol | ||
| Chemical Name | [4-(3-chlorophenyl)piperazin-1-yl]-(5-methyl-2-phenylpyrazol-3-yl)methanone | ||
| SMILES | CC1=NN(C(=C1)C(=O)N2CCN(CC2)C3=CC(=CC=C3)Cl)C4=CC=CC=C4 | ||
| Standard InChIKey | NPHPNBGYPKBDDB-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C21H21ClN4O/c1-16-14-20(26(23-16)18-7-3-2-4-8-18)21(27)25-12-10-24(11-13-25)19-9-5-6-17(22)15-19/h2-9,14-15H,10-13H2,1H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Ras-Net (Elk-3) pathway inhibitor (IC50 = 10 - 20 nM). Indirectly inhibits Net phosphorylation upstream of Erk1/2 activation. Mediates G2-M cell cycle arrest, suppresses growth of multiple cell types (IC50 ~ 2 nM), inhibits angiogenesis and acts as a microtubule depolymerizing agent in vitro. |
XRP44X Dilution Calculator
XRP44X Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.6256 mL | 13.1278 mL | 26.2557 mL | 52.5114 mL | 65.6392 mL |
| 5 mM | 0.5251 mL | 2.6256 mL | 5.2511 mL | 10.5023 mL | 13.1278 mL |
| 10 mM | 0.2626 mL | 1.3128 mL | 2.6256 mL | 5.2511 mL | 6.5639 mL |
| 50 mM | 0.0525 mL | 0.2626 mL | 0.5251 mL | 1.0502 mL | 1.3128 mL |
| 100 mM | 0.0263 mL | 0.1313 mL | 0.2626 mL | 0.5251 mL | 0.6564 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Gomisin O
Catalog No.:BCN2875
CAS No.:72960-22-6
- Gomisin E
Catalog No.:BCN7031
CAS No.:72960-21-5
- 6,7-Dihydroneridienone A
Catalog No.:BCN4020
CAS No.:72959-46-7
- 2-Furoyl-LIGRLO-amide
Catalog No.:BCC3958
CAS No.:729589-58-6
- Carvedilol
Catalog No.:BCC4324
CAS No.:72956-09-3
- DL-Catechin
Catalog No.:BCN6325
CAS No.:7295-85-4
- 30-Hydroxylup-20(29)-en-3-one
Catalog No.:BCN4286
CAS No.:72944-06-0
- Octadecyl p-coumarate
Catalog No.:BCN7235
CAS No.:72943-88-5
- K858
Catalog No.:BCC7760
CAS No.:72926-24-0
- Bohemamine
Catalog No.:BCN1958
CAS No.:72926-12-6
- (RS)-4-Carboxyphenylglycine
Catalog No.:BCC6601
CAS No.:7292-81-1
- α,β-Methyleneadenosine 5'-triphosphate trisodium salt
Catalog No.:BCC3591
CAS No.:7292-42-4
- BMS-707035
Catalog No.:BCC2133
CAS No.:729607-74-3
- Brassinolide
Catalog No.:BCC1438
CAS No.:72962-43-7
- L-(-)-threo-3-Hydroxyaspartic acid
Catalog No.:BCC6565
CAS No.:7298-99-9
- Cordycepin
Catalog No.:BCN5389
CAS No.:73-03-0
- H-Trp-OH
Catalog No.:BCC3111
CAS No.:73-22-3
- Adenine
Catalog No.:BCC4450
CAS No.:73-24-5
- Melatonin
Catalog No.:BCN2196
CAS No.:73-31-4
- H-Ile-OH
Catalog No.:BCC2960
CAS No.:73-32-5
- Guanine
Catalog No.:BCN8414
CAS No.:73-40-5
- Lidocaine hydrochloride
Catalog No.:BCC9009
CAS No.:73-78-9
- 15-Isopimarene-8,18-diol
Catalog No.:BCN4287
CAS No.:73002-86-5
- CyPPA
Catalog No.:BCC7526
CAS No.:73029-73-9
XRP44X, an Inhibitor of Ras/Erk Activation of the Transcription Factor Elk3, Inhibits Tumour Growth and Metastasis in Mice.[Pubmed:27427904]
PLoS One. 2016 Jul 18;11(7):e0159531.
Transcription factors have an important role in cancer but are difficult targets for the development of tumour therapies. These factors include the Ets family, and in this study Elk3 that is activated by Ras oncogene /Erk signalling, and is involved in angiogenesis, malignant progression and epithelial-mesenchymal type processes. We previously described the identification and in-vitro characterisation of an inhibitor of Ras / Erk activation of Elk3 that also affects microtubules, XRP44X. We now report an initial characterisation of the effects of XRP44X in-vivo on tumour growth and metastasis in three preclinical models mouse models, subcutaneous xenografts, intra-cardiac injection-bone metastasis and the TRAMP transgenic mouse model of prostate cancer progression. XRP44X inhibits tumour growth and metastasis, with limited toxicity. Tumours from XRP44X-treated animals have decreased expression of genes containing Elk3-like binding motifs in their promoters, Elk3 protein and phosphorylated Elk3, suggesting that perhaps XRP44X acts in part by inhibiting the activity of Elk3. Further studies are now warranted to develop XRP44X for tumour therapy.
Inhibition of the Ras-Net (Elk-3) pathway by a novel pyrazole that affects microtubules.[Pubmed:18316589]
Cancer Res. 2008 Mar 1;68(5):1275-83.
Net (Elk-3/SAP-2/Erp) is a transcription factor that is phosphorylated and activated by the Ras-extracellular signal-regulated kinase (Erk) signaling pathway and is involved in wound healing, angiogenesis, and tumor growth. In a cell-based screen for small molecule inhibitors of Ras activation of Net transcriptional activity, we identified a novel pyrazole, XRP44X. XRP44X inhibits fibroblast growth factor 2 (FGF-2)-induced Net phosphorylation by the Ras-Erk signaling upstream from Ras. It also binds to the colchicine-binding site of tubulin, depolymerizes microtubules, stimulates cell membrane blebbing, and affects the morphology of the actin skeleton. Interestingly, Combretastin-A4, which produces similar effects on the cytoskeleton, also inhibits FGF-2 Ras-Net signaling. This differs from other classes of agents that target microtubules, which have either little effect (vincristine) or no effect (docetaxel and nocodazole) on the Ras-Net pathway. XRP44X inhibits various cellular properties, including cell growth, cell cycle progression, and aortal sprouting, similar to other molecules that bind to the tubulin colchicine site. XRP44X has the potentially interesting property of connecting two important pathways involved in cell transformation and may thereby represent an interesting class of molecules that could be developed for cancer treatment.
